Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (4189)	1/12/1999 5:32:00 PM
From: CMason	Respond to of 4634

Bill -- Good point, but there hasn't been much "public" hype in the last couple of months, while the stock has gone up considerably. I'm assume they've been hyping through newsletters and the like. I'm evaluating averaging up on my short position. The low burn rate relative to cash on hand, coupled with the unavailability of options, make this a challenging short over the near-term, although I agree with you they're unlikely ever to see an FDA approval for their drug. I am hopeful the stock will start to skid toward fair value as the euphoric first days of the new year become an increasingly distant memory. Regards, CMason

To: Bill Wexler who wrote (4189)	1/13/1999 1:54:00 AM
From: chester lee	Respond to of 4634

<< There is no free lunch when shorting a scam like HEPH or Zonagen>> HEPH also has a lot of cash with a low burn rate. THey can last for years without producing anything. Unfortunately, my short was called-in on a forced buy-in and I lost 70% on my investment. Now the sucker isn't even available. chester